The company has not filed an annual or quarterly report since its Q1 FY2021 10-Q, filed May 5, 2021. Its latest SEC filing is a 15-12G from Jul 26, 2021.
10-Q for Q1 FY2021, filed May 5, 2021
The sections below describe the company as of the FY2020 annual report.
Develops, makes and sells laboratory testing systems, assays and consumables for clinical diagnostic laboratories, pharmaceutical companies and research institutions.
10-K for FY2020, filed Feb 26, 2021We develop, manufacture and sell proprietary biological testing technologies and products with applications throughout the life sciences…View ↗
We continue to focus our commercialization efforts through our strategic partners covering large sectors of the life science research…View ↗
1. Molecular Diagnostics: the development and sale of molecular diagnostic assays utilizing our proprietary MultiCode, xMAP and VERIGENE…View ↗
Our xMAP products are based on an open architecture, multiplexing technology that combines existing biological testing techniques with…View ↗
Customers pay for instruments, assays and consumables, usually when those products ship or are delivered. Partners pay royalties when they report end-user sales; service contracts and upfront technology-license fees bring in revenue over their terms.
10-K for FY2020, filed Feb 26, 2021System revenue is generated from the sale of our xMAP multiplexing analyzers and peripherals, our VERIGENE readers and processors and our…View ↗
Performance Obligations: Revenue is generated primarily from the sale of the Company’s products and related services, which are primarily…View ↗
Royalties: For arrangements that include sales-based royalties, including minimum payments, the Company recognizes revenue at the later of…View ↗
License Revenues: The Company enters into out-licensing agreements, under which it licenses certain rights to its technology to third…View ↗
$417.4M
10-K for FY2020, filed Feb 26, 2021
$417.4M ↗
Clinical diagnostic laboratories buy molecular tests and systems directly; research and pharmaceutical customers are also reached through strategic partners and distributors that sell systems, consumables and assays.
10-K for FY2020, filed Feb 26, 2021We continue to focus our commercialization efforts through our strategic partners covering large sectors of the life science research…View ↗
1. Molecular Diagnostics: the development and sale of molecular diagnostic assays utilizing our proprietary MultiCode, xMAP and VERIGENE…View ↗
We continue to work with these strategic partners as the primary distribution channel for our xMAP Systems, and we will continue to pursue…View ↗
10-K for FY2020, filed Feb 26, 2021
One customer accounted for 10%, 12% and 14% of our total revenues in 2020, 2019 and 2018, respectively. Another customer accounted for 4%…View ↗
Yes. It kept 4 cents of every revenue dollar as net income in FY2020 and turned 8 cents into free cash flow.
10-K for FY2020, filed Feb 26, 2021
$42.4MView ↗
10-K for FY2020, filed Feb 26, 2021
$15.2MView ↗
10-K for FY2020, filed Feb 26, 2021
$32MView ↗
8-K, filed Jul 14, 2021
At the Effective Time of the Merger, each share of common stock, par value $0.001 per share, of the Company (the “Company Common Stock”)…View ↗
Grew. Revenue grew 54% in 4 years, from $270.6M in FY2016 to $417.4M in FY2020, about 11% a year.
Competes with Affymetrix, Life Technologies, Becton, Dickinson, Illumina, Qiagen, Meso Scale Discovery, Quanterix, PerkinElmer, Bio-Rad Laboratories, Abbott Laboratories, BioFire Diagnostics, Cepheid, GenMark Dx, Roche Diagnostics, Siemens Medical Solutions, Hologic, Quidel, Focus Diagnostics, T2 Biosystems, and Accelerate Diagnostics
10-K for FY2020, filed Feb 26, 2021The pharmaceutical industry is a large market for the genomic, protein and high-throughput screening applications supported by xMAP…View ↗
Loading...
